Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Clinical trials have not consistently supported the use of induction chemotherapy (IC) for locally advanced head and neck squamous cell cancer. Hypopharynx and base of tongue (BOT) cancer has shown relatively poor survival. We investigated the role of IC in improving outcome over current chemoradiotherapy (CRT) in patients with hypopharynx and BOT cancer. Methods: Treatment-naïve patients with stage III/IV (M0) hypopharynx or BOT cancer were randomly assigned to receive CRT alone (CRT arm: cisplatin 100 mg/m2 on D1 3-weekly, two times plus radiotherapy 68.4 Gy/30 fractions on weekdays) versus two 21-day cycles of IC with TPF (docetaxel & cisplatin 75 mg/m2 on D1, and fluorouracil 75 mg/m2 on D1-4) followed by the same CRT regimen (IC arm). The primary endpoint was progression-free survival (PFS). Results: This study closed early after enrollment of 36 patients (19 in the CRT arm, 17 in the IC arm). After a median follow-up of 47.2 months, there was no significant difference in PFS: the median PFS was 26.8 months for the CRT arm and was not reached for the IC arm (p = 0.13). However, the survival curves were widely separated with a plateau after 3 years, suggesting a potential survival benefit from IC: 3-year PFS rates were 45% and 68%, and 3-year overall survival rates were 56% and 86%, in the CRT and IC arms, respectively. Conclusions: This study failed to demonstrate that induction TPF chemotherapy improves survival in patients with BOT and hypopharynx cancer. However, it suggested a favorable outcome with IC to this population.
Abstract
Background/Aims: Clinical trials have not consistently supported the use of induction chemotherapy (IC) for locally advanced head and neck squamous cell cancer. Hypopharynx and base of tongue (BOT) cancer has shown relatively poor survival. We investigated the role of IC in improving outcome over current chemoradiotherapy (CRT) in patients with hypopharynx and BOT cancer. Methods: Treatment-naïve patients with stage III/IV (M0) hypopharynx or BOT cancer were randomly assigned to receive CRT alone (CRT arm: cisplatin 100 mg/m2 on D1 3-weekly, two times plus radiotherapy 68.4 Gy/30 fractions on weekdays) versus two 21-day cycles of IC with TPF (docetaxel & cisplatin 75 mg/m2 on D1, and fluorouracil 75 mg/m2 on D1-4) followed by the same CRT regimen (IC arm). The primary endpoint was progression-free survival (PFS). Results: This study closed early after enrollment of 36 patients (19 in the CRT arm, 17 in the IC arm). After a median follow-up of 47.2 months, there was no significant difference in PFS: the median PFS was 26.8 months for the CRT arm and was not reached for the IC arm (p = 0.13). However, the survival curves were widely separated with a plateau after 3 years, suggesting a potential survival benefit from IC: 3-year PFS rates were 45% and 68%, and 3-year overall survival rates were 56% and 86%, in the CRT and IC arms, respectively. Conclusions: This study failed to demonstrate that induction TPF chemotherapy improves survival in patients with BOT and hypopharynx cancer. However, it suggested a favorable outcome with IC to this population.
참고문헌 (14)
- Cohen EE, "Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer", J Clin Oncol, 32, pp.2735~2743 (2014)
- Haddad R, "Induction chemotherapy followed by concurrent chemoradiotherapy(sequential chemoradiotherapy)versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer(PARADIGM) : a randomised phase 3 trial", Lancet Oncol, 14, pp.257~264 (2013)
- Denis F, "Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma", J Clin Oncol, 22, pp.69~76 (2004)
- Pignon JP, "Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93randomised trials and 17,346 patients", Radiother Oncol, 92, pp.4~14 (2009)
- Hitt R, "Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer", J Clin Oncol, 23, pp.8636~8645 (2005)
- Posner MR, "Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer", N Engl J Med, 357, pp.1705~1715 (2007)
- Vermorken JB, "Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer", N Engl J Med, 357, pp.1695~1704 (2007)
- Lim SH, "Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy : implication for subgroup selection for induction chemotherapy", Jpn J Clin Oncol, 46, pp.40~45 (2016)
- Ghi MG, "Concomitant chemoradiation (CRT) or cetuximab", RT (CET, cisplatin, pp.5-fluorouracil (TPF)followed by CRT or CET, RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826)[DOI]
- Posner MR, "Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324 : survival, surgery, and organ preservation", Ann Oncol, 20, pp.921~927 (2009)
- Urba SG, "Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx : a Southwest Oncology Group trial", J Clin Oncol, 23, pp.88~95 (2005)
- Pointreau Y, "Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation", J Natl Cancer Inst, 101, pp.498~506 (2009)
- Janoray G, "Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, ± docetaxel for larynx preservation", J Natl Cancer Inst, 108, pp.djv368~ (2015)
- Mifsud M, "Evolving trends in head and neck cancer epidemiology : Ontario, Canada 1993-2010", Head Neck, 39, pp.1770~1778 (2017)